CY1108629T1 - Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart - Google Patents

Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart

Info

Publication number
CY1108629T1
CY1108629T1 CY20081101393T CY081101393T CY1108629T1 CY 1108629 T1 CY1108629 T1 CY 1108629T1 CY 20081101393 T CY20081101393 T CY 20081101393T CY 081101393 T CY081101393 T CY 081101393T CY 1108629 T1 CY1108629 T1 CY 1108629T1
Authority
CY
Cyprus
Prior art keywords
combination
fluorouracil
medicines
heart
therapeutic treatment
Prior art date
Application number
CY20081101393T
Other languages
Greek (el)
Inventor
Mary Ellen Rybak
Original Assignee
Pharma Mar, S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A.U. filed Critical Pharma Mar, S.A.U.
Publication of CY1108629T1 publication Critical patent/CY1108629T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
CY20081101393T 2003-11-13 2008-12-02 Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart CY1108629T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
EP04798717A EP1689404B9 (en) 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1108629T1 true CY1108629T1 (en) 2014-04-09

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101393T CY1108629T1 (en) 2003-11-13 2008-12-02 Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart

Country Status (15)

Country Link
US (1) US7622458B2 (en)
EP (1) EP1689404B9 (en)
JP (1) JP2007511499A (en)
AT (1) ATE406897T1 (en)
CA (1) CA2544320A1 (en)
CY (1) CY1108629T1 (en)
DE (1) DE602004016376D1 (en)
DK (1) DK1689404T3 (en)
ES (1) ES2314470T3 (en)
HR (1) HRP20080598T3 (en)
PL (1) PL1689404T3 (en)
PT (1) PT1689404E (en)
RS (1) RS50692B (en)
SI (1) SI1689404T1 (en)
WO (1) WO2005049031A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (en) 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.
ATE495793T1 (en) * 2000-11-06 2011-02-15 Pharma Mar Sa ANTITUMOR COMPOSITIONS CONTAINING ECTEINASCIDIN 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
JP2007511499A (en) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー combination
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
PT1827500E (en) * 2004-10-26 2009-08-05 Pharma Mar Sa Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (en) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal FORMULATIONS CONTAINING ECTEINASCIDINE AND DISAHARID
AU2006272343B2 (en) * 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
BR122017028570B1 (en) 2010-11-12 2022-03-03 Pharma Mar, S.A USE OF PM01183, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN SYNERGIC COMBINATION WITH A TOPOISOMERASE I AND/OR II INHIBITOR AND KIT
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
CN111867591A (en) * 2018-02-12 2020-10-30 Array生物制药公司 Methods and combination therapies for treating biliary tract cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (en) 1986-10-21 1988-04-28 Knoll Ag 5-NITROBENZO (DE) ISOCHINOLIN-1,3-DIONE, THEIR PRODUCTION AND USE
FR2697752B1 (en) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
SK285669B6 (en) 1998-04-06 2007-06-07 The Board Of Trustees Of The University Of Illinois Ecteinascidin compound, pharmaceutical composition comprising the same and its use
RU2225864C2 (en) 1998-05-11 2004-03-20 Фарма Мар, С.А. Metabolites of ecteinascidine-743, pharmaceutical composition based on their base and methods for treatment
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (en) 1999-05-14 2004-07-21 Pharma Mar Sa METHOD OF HEMISINTESIS FOR THE FORMATION OF INTERMEDIARY AND DERIVATIVE COMPOUNDS AND OF STRUCTURES RELATED TO ECTEINASCIDINE AND TETRAHYDROISOCHINOLINPHENOLS AND INTERMEDIARY APPLICATION COMPOUNDS IN SUCH METHOD
KR100717916B1 (en) * 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
PT1280809E (en) 2000-04-12 2005-11-30 Pharma Mar Sa ECTEINASCIDINE ANTITUMER DERIVATIVES
CA2418320A1 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE495793T1 (en) 2000-11-06 2011-02-15 Pharma Mar Sa ANTITUMOR COMPOSITIONS CONTAINING ECTEINASCIDIN 743
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (en) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー combination
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2583464A1 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
PT1827500E (en) 2004-10-26 2009-08-05 Pharma Mar Sa Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (en) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal FORMULATIONS CONTAINING ECTEINASCIDINE AND DISAHARID

Also Published As

Publication number Publication date
WO2005049031A1 (en) 2005-06-02
ATE406897T1 (en) 2008-09-15
RS50692B (en) 2010-06-30
CA2544320A1 (en) 2005-06-02
SI1689404T1 (en) 2009-02-28
US7622458B2 (en) 2009-11-24
EP1689404B1 (en) 2008-09-03
PL1689404T3 (en) 2009-02-27
JP2007511499A (en) 2007-05-10
DE602004016376D1 (en) 2008-10-16
DK1689404T3 (en) 2009-01-26
US20070190164A1 (en) 2007-08-16
PT1689404E (en) 2008-12-15
EP1689404A1 (en) 2006-08-16
EP1689404B9 (en) 2009-04-22
HRP20080598T3 (en) 2009-01-31
ES2314470T3 (en) 2009-03-16

Similar Documents

Publication Publication Date Title
CY1108629T1 (en) Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart
DK1551409T3 (en) Use of the quinazoline derivative ZD6474 in combination with gemcitabine and possibly ionizing radiation in the treatment of cancer
CY1105818T1 (en) USES OF ET743 IN THE THERAPEUTIC TREATMENT OF CANCER
DK1169059T3 (en) Docetaxel in combination with rhuMAb HER2 for the treatment of cancers
PT1173178E (en) COMPOSITION UNDERSTANDING APOMORPHINE AND SILDENAFIL AND USES THEMSELVES FOR THE TREATMENT OF ERECTILE DISFUNCTION
NO20032027D0 (en) Effective anti-tumor treatments
NO20072543L (en) Anti-cancer treatment
BR0313117A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect in a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and , use of zd6474 or a pharmaceutically acceptable salt thereof and zd1839 or a pharmaceutically acceptable salt thereof
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
BRPI0508982A (en) use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt, pharmaceutical composition, kit, method for treating a cancer in a warm-blooded animal such as a human, and use of azd2171 maleate salt azd2171 and 5 - fu and cpt - 11
IL164564A0 (en) Combination therapy for the treatment of cancer
BR0009380A (en) Improved cancer treatment with temozozomide
NO20031410D0 (en) Antitumor therapy including distamycin derivatives
PT1408977E (en) COMBINATION THERAPY FOR CARDIAC FAILURE TREATMENT
PT1251850E (en) USE OF A PREPARATION OF COMBINATION IN CANCER THERAPY
ATE345805T1 (en) CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
DE60308403D1 (en) COMBINATION THERAPY WITH GEMZITABIN AND ZD6126
RU2004107473A (en) METHOD FOR THERAPY OF CHRONIC OVERSTRAINING OF AN ATHLETES
UA3976U (en) METHOD OF TREATMENT OF LOCAL NON-RESECTABLE COLON CANCER
UA11290U (en) Method for preventing antracyclin-associated heart lesions
RU2002106480A (en) A method for the treatment of advanced forms of malignant tumors
BRPI0407301A (en) Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.